title: [Targeted therapies in oncology].
abstract: The development of anticancer targeted therapies is the result of a knowledge transfer from biology research to clinical practice. Indeed these drugs act on proliferation signal pathways involved in oncogenesis. Monoclonal antibodies (antiHER1 or cetuximab, antiHER2 or trastuzimab, antiVEGF or bevacizumab...) or inhibitor proteins (antiHER1 or cetuximab, antityrosine kinase c-Kit or imatinib...) are used in the treatment of several cancers types (breast, colon-rectum, lung, kidney...) alone or in association with chemotherapies since they improve patients' prognosis and survival. However additional clinical studies are still required to optimize their administration.
authors.affiliation: Service d'oncologie médicale, Institut de cancérologie de la Loire, 42271 Saint-Priest-en-Jarez Cedex.
authors.forename: Cécile
authors.initials: C
authors.lastname: Fournel-Federico
authors.forename: Benoît
authors.initials: B
authors.lastname: You
authors.forename: Véronique
authors.initials: V
authors.lastname: Trillet-Lenoir
mesh_terms: D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*